𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis C treatment response kinetics and impact of baseline predictors

✍ Scribed by M. Lindh; B. Arnholm; A. Eilard; M. Färkkilä; K. Hellstrand; M. Lagging; N. Langeland; K. Mørch; S. Nilsson; C. Pedersen; M. R. Buhl; T. Wahlberg; R. Wejstål; J. Westin; G. Norkrans

Book ID
108886468
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
284 KB
Volume
18
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of response of U.S. veterans
Predictors of response of U.S. veterans to treatment for the hepatitis C virus
✍ Lisa I. Backus; Derek B. Boothroyd; Barbara R. Phillips; Larry A. Mole 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

The currently recommended treatment for hepatitis C virus (HCV) infection is pegylated interferon alfa (PEG-INF) and ribavirin, which can be difficult to tolerate. More information about predicting sustained virologic response (SVR) may allow more informed treatment decisions to be made. This retros

Predictors of sustained virological resp
Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation
✍ Matteo Cescon; Gian Luca Grazi; Alessandro Cucchetti; Gaetano Vetrone; Matteo Ra 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

Factors associated with sustained virological response (SVR) in patients treated for hepatitis C virus (HCV) recurrence after liver transplantation (LT) are unclear. Ninety-nine HCV-positive/hepatitis B surface antigen-negative patients received antiviral treatment (AVT) with interferon/peginterfero

Health-related quality of life in chroni
Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response
✍ John E. Ware Jr; Martha S. Bayliss; Michael Mannocchia; Gary L. Davis 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

Hepatitis C infects nearly 4 million Americans. Most have chronic hepatitis C (CHC), which progresses to cirrhosis in about 20% of patients. Interferon treatment leads to transient responses in about 40% of patients and apparent eradication of infection in 7% to 40% of patients. In this report, we d